Gorman C, Leandro M, Isenberg D
Centre for Rheumatology, The Middlesex Hospital, University College London, UK.
Lupus. 2004;13(5):312-6. doi: 10.1191/0961203304lu1018oa.
B cell dysfunction and pathogenic autoantibody formation are thought to be critical in the pathogenesis of systemic lupus erythematosus (SLE). In this review we will summarize the results of attempts to utilize B cell depletion, based on the use of a chimeric monoclonal antibody (MAb) specific for human CD20, rituximab, for the treatment of patients with SLE.
B细胞功能障碍和致病性自身抗体的形成被认为在系统性红斑狼疮（SLE）的发病机制中起关键作用。在本综述中，我们将总结基于使用针对人CD20的嵌合单克隆抗体（MAb）利妥昔单抗进行B细胞清除来治疗SLE患者的尝试结果。
